Gaspar Nathalie, Di Giannatale Angela, Geoerger Birgit, Redini Françoise, Corradini Nadège, Enz-Werle Natacha, Tirode Franck, Marec-Berard Perrine, Gentet Jean-Claude, Laurence Valérie, Piperno-Neumann Sophie, Oberlin Odile, Brugieres Laurence
Department of Oncology for Children and Adolescents, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France.
Sarcoma. 2012;2012:301975. doi: 10.1155/2012/301975. Epub 2012 Nov 27.
Primary malignant bone tumours, osteosarcomas, and Ewing sarcomas are rare diseases which occur mainly in adolescents and young adults. With the current therapies, some patients remain very difficult to treat, such as tumour with poor histological response to preoperative CT (or large initial tumour volume for Ewing sarcomas not operated), patients with multiple metastases at or those who relapsed. In order to develop new therapies against these rare tumours, we need to unveil the key driving factors and molecular abnormalities behind the malignant characteristics and to broaden our understanding of the phenomena sustaining the metastatic phenotype and treatment resistance in these tumours. In this paper, starting with the biology of these tumours, we will discuss potential therapeutic targets aimed at increasing local tumour control, limiting metastatic spread, and finally improving patient survival.
原发性恶性骨肿瘤、骨肉瘤和尤因肉瘤是罕见疾病,主要发生在青少年和青年成人中。采用目前的治疗方法,一些患者仍然很难治疗,比如对术前CT组织学反应不佳的肿瘤(或未接受手术的尤因肉瘤初始肿瘤体积较大)、有多处转移的患者或复发患者。为了开发针对这些罕见肿瘤的新疗法,我们需要揭示恶性特征背后的关键驱动因素和分子异常,并加深对维持这些肿瘤转移表型和治疗抗性现象的理解。在本文中,我们将从这些肿瘤的生物学特性入手,讨论旨在提高局部肿瘤控制、限制转移扩散并最终改善患者生存率的潜在治疗靶点。